# Takeda notified Denali Therapeutics regarding the termination of their collaboration agreement to co-develop DNL593.

*biotech · news · 2026-04-06 · Benzinga*

## Key points

- Takeda has terminated its partnership with Denali for DNL593 for strategic, not safety, reasons.
- Denali regains full control and intellectual property rights for DNL593 after Takeda's exit.
- Phase 1/2 trial results for DNL593 are expected to be reported by the end of 2026.
- Early trial data show DNL593 increases cerebrospinal fluid progranulin in a dose-dependent manner.

**Companies:** Takeda, Denali Therapeutics
**Countries:** Japan, United States

[Read the full story on Benzinga](https://www.benzinga.com/markets/biotech/26/04/51664830/takeda-exits-dementia-drug-partnership-with-denali-therapeutics-heres-why)

---

Canonical: https://newsio.io/n/39f214e9-af33-4cf7-933b-54f89c9a7a75/takeda-notified-denali-therapeutics-regarding-the-termination-of-their-collabora
Summarized by Newsio from Benzinga. https://newsio.io/how-it-works